**Question:** Which of the following 5-HT3 blockers has highest receptor affinity -

A. Ondansetron
B. Rizatriptan
C. Alosetron
D. Granisetron

**Core Concept:** 5-HT3 receptors are a subtype of ion channels found primarily on the sensory neurons involved in vomiting reflex, and also on the vagus nerve and gastrointestinal tract. Antagonists of these receptors are used as antiemetic agents to prevent nausea and vomiting associated with chemotherapy or surgery.

**Why the Correct Answer is Right:** Granisetron has the highest receptor affinity among the given options. Granisetron is a highly selective 5-HT3 receptor antagonist with a higher binding affinity for the 5-HT3 receptor compared to the other options. This higher affinity makes it more effective in blocking the vomiting reflex and preventing nausea and vomiting.

**Why Each Wrong Option is Incorrect:**

A. Ondansetron: Ondansetron is also a selective 5-HT3 receptor antagonist, but its binding affinity is lower than that of Granisetron. This results in slightly reduced efficacy in controlling nausea and vomiting compared to Granisetron.

B. Rizatriptan: Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for treating migraine. It does not have any significant 5-HT3 receptor antagonist properties, so its affinity for 5-HT3 receptors is much lower than Granisetron.

C. Alosetron: Alosetron is a highly selective 5-HT4 receptor antagonist, primarily used for treating irritable bowel syndrome. Although it does have some 5-HT3 receptor antagonist properties, its binding affinity for 5-HT3 receptors is lower than Granisetron.

D. Granisetron: As explained above, Granisetron has the highest receptor affinity for 5-HT3 receptors among the given options. Its effectiveness in controlling nausea and vomiting is the result of this high binding affinity.

**Clinical Pearl:** High receptor affinity is crucial for the efficacy of 5-HT3 receptor antagonists in preventing nausea and vomiting. Granisetron has the highest affinity, making it an optimal choice for antiemetic therapy in cancer chemotherapy-induced nausea and vomiting, as well as postoperative nausea and vomiting.